• 1
    Wolfe F, Zhao S, Lane N. Preference for nonsteroidal antiinflammatory drugs over acetaminophen by rheumatic disease patients: a survey of 1,799 patients with osteoarthritis, rheumatoid arthritis, and fibromyalgia. Arthritis Rheum 2000; 43: 37885.
  • 2
    Roth SH. NSAIDs gastropathy: a new understanding. Arch Intern Med 1996; 156: 16238.
  • 3
    Singh G, Ramey DR, Mortfeld HS, Shi H, Hatoum HT, Fries JF. Gastrointestinal tract complications of nonsteroidal anti-inflammatory drug treatment in rheumatoid arthritis. Arch Intern Med 1996; 156: 15306.
  • 4
    Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 1999; 340: 188899.
  • 5
    Tannenbaum H, Davis P, Russell AS, Atkinson MH, Maksymowych W, Huang SH, et al. An evidence-based approach to prescribing NSAIDs in musculoskeletal disease: a Canadian consensus. CMAJ 1996; 155: 7788.
  • 6
    Hochberg MC, Altman RD, Brandt KD, Clark BM, Dieppe PA, Griffin MR, et al. Guidelines for the medical management of osteoarthritis. Part II. Osteoarthritis of the knee. Arthritis Rheum 1995; 38: 15416.
  • 7
    American College of Rheumatology Ad Hoc Committee on Clinical Guidelines. Guidelines for the management of rheumatoid arthritis. Arthritis Rheum 1996; 39: 71322.
  • 8
    Lanza FL. A guideline for the treatment and prevention of NSAID-induced ulcers. Gastroenterology 1998; 93: 203746.
  • 9
    Hernandez-Diaz S, Garcia Rodriguez LA. Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation: an overview of epidemiologic studies published in the 1990s. Arch Intern Med 2000; 160: 20939.
  • 10
    Blower AL, Brooks P, Fenn GC, Hill A, Pearce MY, Morant S, et al. Emergency admissions for upper gastrointestinal disease and their relation to NSAID use. Aliment Pharmacol Ther 1997; 11: 28391.
  • 11
    Emery P, Zeidler H, Kvien TK, Guslandi M, Naudin R, Stead H, et al. Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison. Lancet 1999; 354: 210611.
  • 12
    Bensen WG, Fiechther JJ, McMillen JI, Zhao WW, Yu SS, Woods EM, et al. Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: a randomized controlled trial. Mayo Clin Proc 1999; 74: 1095105.
  • 13
    Ehrich EW. Effect of specific COX-2 inhibition in osteoarthritis of the knee: a 6-week double blind placebo controlled pilot study of rofecoxib. J Rheumatol 1999; 26: 243847.
  • 14
    Cannon GW, Caldwell JR, Holt P, McLean B, Seidenberg B, Bolognese J, et al, for the Rofecoxib Phase III Protocol 035 Study Group. Rofecoxib, a specific inhibitor of cyclooxygenase 2, with clinical efficacy comparable with that of diclofenac sodium: results of a one-year, randomized, clinical trial in patients with osteoarthritis of the knee and hip. Arthritis Rheum 2000; 43: 97887.
  • 15
    Simon LS, Weaver AL, Graham DY, Kivitz AJ, Lipsky PE, Hubbard RC, et al. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial. JAMA 1999; 282: 19218.
  • 16
    Goldstein JL, Silverstein FE, Agrawal NM, Hubbard RC, Kaiser J, Maurath CJ, et al. Reduced risk of upper gastrointestinal ulcer complications with celecoxib, a novel COX-2 inhibitor. Am J Gastroenterol 2000; 95: 168190.
    Direct Link:
  • 17
    Langman MJ, Jensen DM, Watson DJ, Harper SE, Zhao PL, Quan H, et al. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. JAMA 1999; 282: 192933.
  • 18
    Brooks P, Emery P, Evans JF, Fenner H, Hawkey CJ, Patrono C, et al. Interpreting the clinical significance of the differential inhibition of cyclooxygenase-1 and cyclooxygenase-2. Rheumatology 1999; 38: 77988.
  • 19
    Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000; 284: 124755.
  • 20
    Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, et al, VIGOR Study Group. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000; 343: 15208.
  • 21
    Hawkey CJ, Laine L, Simon LS, Beaulieu A, Maldonado-Cocco J, Acevedo E, et al. Comparison of the effects of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen and placebo on gastroduodenal mucosa of patients with osteoarthritis: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2000; 43: 3707.
  • 22
    Simon LS. Role and regulation of cyclooxygenase-2 during inflammation, position paper by expert panel on COX-1/COX-2. Am J Med 1999; 1065B: 37S42S.
  • 23
    Emery P. Cyclooxygenase-2: a major therapeutic advance? Am J Med 2001; 1101 Suppl 1: S42S45.
  • 24
    Watson DJ, Harper SE, Zhao PL, Quan H, Bolognese JA, Simon TJ. Gastrointestinal tolerability of the selective cyclooxygenase-2 (COX-2) inhibitor rofecoxib compared with non-selective COX-1/COX-2 inhibitors in osteoarthritis. Arch Intern Med 2000; 160: 29983003.
  • 25
    Komhoff M, Grone H-J, Klein T, Seyberth HW, Nusing RM. Localisation of cyclooxygenase-1 and -2 in adult and fetal human kidney: implications of renal function. Am J Physiol 1997; 272: F4608.
  • 26
    Schnitzer T. Cyclooxygenase-2–specific inhibitors: are they safe? Am J Med 2001; 1101A: 46S9S.
  • 27
    Peterson WL, Cryer B. Cox-1 sparing NSAIDs: is the enthusiasm justified? JAMA 1999; 282: 19613.
  • 28
    Chancellor JV, Hunsche E, de Cruz E, Sarasin FP. Economic evaluation of celecoxib, a new cyclo-oxygenase 2 specific inhibitor, in Switzerland. Pharmacoeconomics 2001; 19 Suppl 1: 5975.
  • 29
    Pellissier JM, Straus WL, Watson DJ, Kong SX, Harper SE. Economic evaluation of rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs for the treatment of osteoarthritis. Clin Ther 2001; 23: 106179.
  • 30
    Haglund U, Svarvar P. The Swedish ACCES model: predicting the health economic impact of celecoxib in patients with osteoarthritis or rheumatoid arthritis. Rheumatology 2000; 39 Suppl 2: 516.
  • 31
    Cox-2 agents' impact on NSAID and GI drug use and cost: what's been seen in practice? Formulary 2000; 35: 715.
  • 32
    Régie de l'Assurance Maladie du Québec. URL: Accessed: October 10, 2001.
  • 33
    Garcia Rodriguez LA, Hernandez-Diaz S. Risk of upper gastrointestianl complications among users of acetaminophen and nonsteroidal anti-inflammatory drugs. Epidemiology 2001; 12: 5706.
  • 34
    Moore N, Van Ganse E, Le Parc JM, Wall R, Schneid H, Farhan M, et al. The Pain Study: paracetamol, aspirin, ibuprofen new tolerability: a large scale, randomised clinical trial comparing the tolerability of aspirin, ibuprofen and paracetamol for short term analgesia. Clin Drug Invest 1999; 18: 8998.
  • 35
    Locke GR III, Fett SL, Talley NJ, Fett SL, Melton LJ. Risk factors for irritable bowel syndrome: role of analgesics and food sensitivities. Am J Gastroenterol 2000; 95: 15765.
    Direct Link:
  • 36
    Aldoori WH, Giovannucci EL, Rimm EB, Wing AL, Willett WC. Use of acetaminophen and nonsteroidal anti-inflammatory drugs: a prospective study and the risk of symptomatic diverticular disease in men. Arch Fam Med 1998; 7: 25560.
  • 37
    Green K, Drvota V, Vesterqvist O. Pronounced reduction in in vivo prostacyclin synthesis in humans by acetaminophen (paracetamol). Prostaglandins 1989; 37: 3115.
  • 38
    Insel PA. Analgesic-antipyretic and anti-inflammatory agents and drugs employed in the treatment of gout. In: HardmanJG, LimbridLE, editors. Goodman & Gilman's The pharmacological basis of therapeutics. 9th ed. New York: McGraw-Hill; 1996. p. 6313.
  • 39
    Rahme E, Joseph L, Kong SX, Watson DJ, LeLorier J. Gastrointestinal health care resource use and costs associated with nonsteroidal antiinflammatory drugs versus acetaminophen: retrospective cohort study of an elderly population. Arthritis Rheum 2000; 43: 91724.
  • 40
    Garbe E, LeLorier J, Boivin J-F, Suissa S. Risk of ocular hypertension or open-angle glaucoma in elderly patients on oral glucocorticoids. Lancet 1997; 350: 97982.
  • 41
    Pincus T, Koch GG, Sokka T, Lefkowith J, Wolfe F, Jordan JM, et al. A randomized, double-blind, crossover clinical trial of diclofenac plus misoprostol versus acetaminophen in patients with osteoarthritis of the hip or knee. Arthritis Rheum 2001; 44: 158798.
  • 42
    Geba GP, Weaver AL, Polis AB, Dixon ME, Schnitzer TJ. Efficacy of rofecoxib, celecoxib, and acetaminophen in osteoarthritis of the knee: a randomized trial. JAMA 2002; 287: 6471.
  • 43
    Pellissier JM, Straus WL, Watson DJ, Kong SX, Harper SE. Economic evaluation of rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs for the treatment of osteoarthritis. Clin Ther 2001; 23: 106173.
  • 44
    Marshall JK, Pellissier JM, Attard CL, Kong SX, Marentette MA. Incremental cost-effectiveness analysis comparing rofecoxib with nonselective NSAIDs in osteoarthritis. Pharmacoeconomics 2001; 19: 103949.